SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 222.15 |
| Enterprise Value ($M) | 157.75 |
| Book Value ($M) | 167.02 |
| Book Value / Share | 4.18 |
| Price / Book | 1.33 |
| NCAV ($M) | 134.69 |
| NCAV / Share | 3.37 |
| Price / NCAV | 1.65 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.53 |
| Return on Assets (ROA) | -0.55 |
| Return on Equity (ROE) | -0.71 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.85 |
| Current Ratio | 7.85 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 179.49 |
| Assets | 211.83 |
| Liabilities | 44.80 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Flynn James E | 0.00 | -100.00 | |
| 13G | Vestal Point Capital, LP | 7.30 | ||
| 13D/A | Perceptive Advisors Llc | 17.30 | 0.14 | |
| 13G/A | Adage Capital Management, L.P. | 4.55 | ||
| 13G/A | Invus Global Management, LLC | 7.10 | 9.60 | |
| 13G/A | Millennium Management Llc | 2.90 | -44.53 | |
| 13D/A | Ra Capital Management, L.p. | 11.30 | 0.22 | |
| 13D/A | BCLS SB Investco, LP | 6.00 | 0.00 | |
| 13G | Adage Capital Partners Gp, L.l.c. | 7.25 | ||
| 13G | Artal International S.C.A. | 7.30 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 115,090 | 373,272 | 30.83 | |
| 122,064 | 282,241 | 43.25 | |
| 47,794 | 198,868 | 24.03 | |
| 46,580 | 206,358 | 22.57 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SANA – Sana Biotechnology, Inc. | SCPH – scPharmaceuticals Inc. |
| SDGR – Schrödinger, Inc. | SLRN – Acelyrin, Inc. |
| SNDX – Syndax Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io